STOCK TITAN

Organon (OGN) EVP gains shares via RSU vesting and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Organon & Co. Executive VP, Corp. Dev. Daniel Karp exercised 14,184 Restricted Stock Units into common stock. The RSUs converted one-for-one into Organon shares at a stated price of $0.00 per unit.

To satisfy tax obligations, 4,446 shares of common stock were withheld at a reference price of $5.84 per share, based on the closing market price on March 27, 2026 as required under the plan. Following these transactions, Karp directly holds 57,153.923 shares of Organon common stock, which includes 746.463 shares acquired from dividend equivalents net of withholding tax. The RSUs vest and are distributed in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

Positive

  • None.

Negative

  • None.
Insider Karp Daniel
Role Executive VP, Corp. Dev.
Type Security Shares Price Value
Exercise Restricted Stock Units 14,184 $0.00 --
Exercise Common Stock 14,184 $0.00 --
Tax Withholding Common Stock 4,446 $5.84 $26K
Holdings After Transaction: Restricted Stock Units — 14,185 shares (Direct); Common Stock — 60,853.46 shares (Direct)
Footnotes (1)
  1. This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Includes the addition of 746.463 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Each RSU converts into one share of Organon common stock. These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
RSUs exercised 14,184 units Restricted Stock Units converted to common stock on March 29, 2026
Tax-withholding shares 4,446 shares at $5.84 Shares delivered to cover tax liability on March 29, 2026
Post-transaction holdings 57,153.923 shares Common stock directly held by Daniel Karp after transactions
Dividend equivalent shares 746.463 shares Common stock from dividend equivalents net of withholding tax
RSU vesting schedule 3 equal installments Vesting on March 29, 2025, 2026, and 2027
Restricted Stock Units financial
"The RSUs converted one-for-one into Organon shares at a stated price"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
dividend equivalents financial
"includes 746.463 shares of Organon common stock acquired from dividend equivalents"
Payments tied to employee or contractor equity awards that mirror the cash dividends paid on the company’s stock; they give the holder the same economic benefit as owning the shares without transferring actual shares—often paid in cash or additional award units when the award becomes payable. Investors care because these payments affect a company’s compensation costs, cash flow and potential share dilution, and they signal how management is being rewarded and aligned with shareholders.
tax-withholding disposition financial
"transaction_action was a tax-withholding disposition of 4,446 shares"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
exercise or conversion of derivative security financial
"transaction_code_description notes an exercise or conversion of derivative security"
closing market price financial
"price is the closing market price of Organon common stock on March 27, 2026"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Karp Daniel

(Last)(First)(Middle)
C/O ORGANON & CO.
30 HUDSON STREET, FLOOR 33

(Street)
JERSEY CITY NEW JERSEY 07032

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Executive VP, Corp. Dev.
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/29/2026M14,184A$060,853.46D
Common Stock03/29/2026F4,446D$5.84(1)57,153.923(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(3)03/29/2026M14,184 (4) (4)Common Stock14,184$014,185D
Explanation of Responses:
1. This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
2. Includes the addition of 746.463 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported.
3. Each RSU converts into one share of Organon common stock.
4. These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
Remarks:
Exhibit 24-Power of Attorney
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Daniel Karp03/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Organon (OGN) report for Daniel Karp?

Organon reported that Executive VP, Corp. Dev. Daniel Karp exercised 14,184 Restricted Stock Units into common stock. The transaction reflects routine equity compensation vesting rather than an open-market stock purchase or sale, and is recorded as a derivative exercise on March 29, 2026.

How many Organon (OGN) shares does Daniel Karp hold after this Form 4?

After the reported transactions, Daniel Karp directly holds 57,153.923 shares of Organon common stock. This total includes 746.463 shares acquired from dividend equivalents, net of withholding tax, in addition to shares received from the RSU conversion and shares remaining after tax withholding.

What was the size of the RSU exercise reported for Organon (OGN)?

The filing shows Daniel Karp exercised 14,184 Restricted Stock Units, each converting into one share of Organon common stock. The RSUs carried a stated exercise or conversion price of $0.00 per unit, consistent with equity awards that vest into shares rather than being purchased for cash.

How many Organon (OGN) shares were withheld for taxes in this Form 4?

The filing indicates 4,446 shares of Organon common stock were disposed of as a tax-withholding transaction. These shares were valued at $5.84 per share, matching the closing market price on March 27, 2026, and were delivered to satisfy tax obligations tied to the RSU vesting.

How do Daniel Karp’s Organon (OGN) RSUs vest over time?

The RSUs reported vest and are distributed as Organon common stock in three equal installments. The scheduled vesting dates are March 29, 2025, March 29, 2026, and March 29, 2027, reflecting a multi-year equity compensation structure for the executive.

What does each Organon (OGN) RSU convert into for Daniel Karp?

Each Restricted Stock Unit converts into one share of Organon common stock according to the filing. This one-for-one conversion means the 14,184 RSUs exercised resulted in 14,184 shares before accounting for any shares withheld to cover associated tax liabilities.